Castleark Management LLC bought a new stake in Sientra Inc (NASDAQ:SIEN) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 151,590 shares of the medical instruments supplier’s stock, valued at approximately $2,958,000. Castleark Management LLC owned 0.53% of Sientra as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Metropolitan Life Insurance Co. NY acquired a new position in Sientra during the second quarter worth about $160,000. Commonwealth Equity Services LLC purchased a new stake in shares of Sientra in the 2nd quarter valued at approximately $210,000. MetLife Investment Advisors LLC purchased a new stake in shares of Sientra in the 2nd quarter valued at approximately $226,000. Barclays PLC raised its stake in shares of Sientra by 133.7% in the 1st quarter. Barclays PLC now owns 31,521 shares of the medical instruments supplier’s stock valued at $304,000 after acquiring an additional 18,033 shares during the period. Finally, Rhumbline Advisers raised its stake in shares of Sientra by 55.6% in the 2nd quarter. Rhumbline Advisers now owns 21,621 shares of the medical instruments supplier’s stock valued at $422,000 after acquiring an additional 7,725 shares during the period. Institutional investors and hedge funds own 89.22% of the company’s stock.
SIEN has been the topic of several recent research reports. BidaskClub downgraded shares of Sientra from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 31st. Dougherty & Co initiated coverage on shares of Sientra in a research note on Thursday, August 30th. They set a “buy” rating and a $31.00 target price on the stock. Zacks Investment Research downgraded shares of Sientra from a “hold” rating to a “sell” rating in a research note on Friday, September 21st. Stifel Nicolaus increased their price objective on shares of Sientra from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, August 8th. Finally, Stephens reissued a “buy” rating and issued a $30.00 price objective on shares of Sientra in a research report on Thursday, August 9th. One research analyst has rated the stock with a sell rating, ten have given a buy rating and one has assigned a strong buy rating to the company. Sientra presently has an average rating of “Buy” and a consensus price target of $22.50.
Shares of Sientra stock traded up $0.89 during trading hours on Friday, hitting $21.46. The company had a trading volume of 343,696 shares, compared to its average volume of 422,977. Sientra Inc has a twelve month low of $8.79 and a twelve month high of $26.79. The company has a current ratio of 3.06, a quick ratio of 2.63 and a debt-to-equity ratio of 0.27. The stock has a market cap of $678.85 million, a price-to-earnings ratio of -7.61 and a beta of -0.78.
Sientra (NASDAQ:SIEN) last issued its earnings results on Tuesday, August 7th. The medical instruments supplier reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.04). Sientra had a negative net margin of 131.16% and a negative return on equity of 151.47%. The company had revenue of $17.55 million during the quarter, compared to analyst estimates of $15.30 million. On average, analysts forecast that Sientra Inc will post -2.93 earnings per share for the current fiscal year.
In related news, CEO Jeffrey M. Nugent sold 1,852 shares of the stock in a transaction on Friday, August 31st. The shares were sold at an average price of $24.90, for a total transaction of $46,114.80. Following the completion of the sale, the chief executive officer now owns 297,999 shares in the company, valued at approximately $7,420,175.10. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 31.00% of the stock is owned by corporate insiders.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
See Also: Earnings Per Share (EPS)
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.